Abbie Celniker, Ph.D.
Third Rock Ventures
Abbie Celniker brings 30 years of experience in R&D and senior leadership roles. A partner at Third Rock Ventures, she focuses on the formation, development and strategy of portfolio companies. She has served as president and CEO of Eleven Biotherapies and Taligen Therapeutics and as a board member and interim chief executive officer at Goldfinch Bio. Abbie has also served as the global head of biologics of Novartis AG, the senior vice president of R&D strategy and operations of Millennium Pharmaceuticals (now Takeda) and the vice president of protein technologies of the Wyeth Research facilities. Abbie is a member of the MassBio board of directors, a member of the board of ImaginAb, where she was previously the chair, and a member of the scientific advisory board for Adimab. She is also a member of the board of directors of the nonprofit Unitio and T1D. She has a B.A. in biology from the University of California, San Diego, and a Ph.D. in molecular biology from the University of Arizona.